BioCentury | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

...for Celgene Corp.’s myeloid portfolio, succeeds Andrew Obenshain. He becomes “chief of wings” at bluebird. Personalized cancer therapy...
BioCentury | Oct 15, 2019
Tools & Techniques

Yale takes CRISPR beyond editing, turning cold tumors hot

A Yale team has developed a new use for CRISPR as a cancer vaccine that turns cold tumors hot by boosting neoantigen expression, rather than editing genes. In the realm of cancer, CRISPR’s application to...
BioCentury | Oct 4, 2019
Company News

Management tracks: J&J hires Bayer’s Swanson; plus Torque, Dynavax, Pact, Deciphera, NextCure, Retrophin, Verve, Jnana and more

...no immediate plans to replace Coffman, citing its recent restructuring around its vaccine business. TCR-based personalized cancer therapy...
BioCentury | Sep 13, 2019
Company News

Management tracks: Orchard, Black Diamond, ALK-Abelló, Menarini, Imvax, Rallybio, Milestone, MaaT and more

...CEO. He succeeds co-founder and CMO David Andrews, who was serving as interim CEO. The personalized cancer therapy...
BioCentury | Sep 5, 2019
Company News

Management tracks: Locana, Synlogic, Farcast, Oncology Venture, Cala, Novaremed, Sidley Austin and Logos Capital

...Sciences Corp. (NASDAQ:EXAS), succeeds co-founder Mallik Sundaram. Farcast was formerly known as Mitra RxDx Inc. Personalized cancer therapy...
BioCentury | May 30, 2019
Finance

Santé seeks bigger stakes with $250M new fund

...Geneos Therapeutics Inc., a spinout from Inovio Pharmaceuticals Inc. (NASDAQ:INO) with a neoantigen-based platform for personalized cancer therapy...
BioCentury | Apr 25, 2019
Financial News

BostonGene raises $50M series A to develop personalized cancer therapy software

BostonGene will deploy its $50 million series A funds to scale and develop its cloud-based platform for determining optimal patient-specific cancer therapies. NEC Corp. is the sole investor in the untranched financing announced on Wednesday....
BioCentury | Nov 12, 2018
Preclinical News

Sequencing-based method identifies neoantigen-specific TCRs

In a Nature Biotechnology paper , researchers described a method to identify TCRs that bind to specific neoantigens, which could enable efficient and inexpensive production of personalized T cell therapies. The high-throughput technique, developed by researchers...
BioCentury | Feb 10, 2017
Company News

Perthera, Novartis deal

...terms. Perthera Inc. , McLean, Va. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Cancer Nora Weintraub Novartis AG Perthera...
BioCentury | Sep 22, 2016
Translation in Brief

Precision traffic control

...Following its July $8.7 million series A funding round, Perthera Inc. is building up its precision...
...to expert guidance on which tests to order and how to interpret results. Emanuel Petricoin, Perthera's...
...Perthera enters a clinical trial. The series A funding and the current fees should help Perthera...
Items per page:
1 - 10 of 19
BioCentury | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

...for Celgene Corp.’s myeloid portfolio, succeeds Andrew Obenshain. He becomes “chief of wings” at bluebird. Personalized cancer therapy...
BioCentury | Oct 15, 2019
Tools & Techniques

Yale takes CRISPR beyond editing, turning cold tumors hot

A Yale team has developed a new use for CRISPR as a cancer vaccine that turns cold tumors hot by boosting neoantigen expression, rather than editing genes. In the realm of cancer, CRISPR’s application to...
BioCentury | Oct 4, 2019
Company News

Management tracks: J&J hires Bayer’s Swanson; plus Torque, Dynavax, Pact, Deciphera, NextCure, Retrophin, Verve, Jnana and more

...no immediate plans to replace Coffman, citing its recent restructuring around its vaccine business. TCR-based personalized cancer therapy...
BioCentury | Sep 13, 2019
Company News

Management tracks: Orchard, Black Diamond, ALK-Abelló, Menarini, Imvax, Rallybio, Milestone, MaaT and more

...CEO. He succeeds co-founder and CMO David Andrews, who was serving as interim CEO. The personalized cancer therapy...
BioCentury | Sep 5, 2019
Company News

Management tracks: Locana, Synlogic, Farcast, Oncology Venture, Cala, Novaremed, Sidley Austin and Logos Capital

...Sciences Corp. (NASDAQ:EXAS), succeeds co-founder Mallik Sundaram. Farcast was formerly known as Mitra RxDx Inc. Personalized cancer therapy...
BioCentury | May 30, 2019
Finance

Santé seeks bigger stakes with $250M new fund

...Geneos Therapeutics Inc., a spinout from Inovio Pharmaceuticals Inc. (NASDAQ:INO) with a neoantigen-based platform for personalized cancer therapy...
BioCentury | Apr 25, 2019
Financial News

BostonGene raises $50M series A to develop personalized cancer therapy software

BostonGene will deploy its $50 million series A funds to scale and develop its cloud-based platform for determining optimal patient-specific cancer therapies. NEC Corp. is the sole investor in the untranched financing announced on Wednesday....
BioCentury | Nov 12, 2018
Preclinical News

Sequencing-based method identifies neoantigen-specific TCRs

In a Nature Biotechnology paper , researchers described a method to identify TCRs that bind to specific neoantigens, which could enable efficient and inexpensive production of personalized T cell therapies. The high-throughput technique, developed by researchers...
BioCentury | Feb 10, 2017
Company News

Perthera, Novartis deal

...terms. Perthera Inc. , McLean, Va. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Cancer Nora Weintraub Novartis AG Perthera...
BioCentury | Sep 22, 2016
Translation in Brief

Precision traffic control

...Following its July $8.7 million series A funding round, Perthera Inc. is building up its precision...
...to expert guidance on which tests to order and how to interpret results. Emanuel Petricoin, Perthera's...
...Perthera enters a clinical trial. The series A funding and the current fees should help Perthera...
Items per page:
1 - 10 of 19